These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 24118558)

  • 1. hERG inhibitors with similar potency but different binding kinetics do not pose the same proarrhythmic risk: implications for drug safety assessment.
    DI Veroli GY; Davies MR; Zhang H; Abi-Gerges N; Boyett MR
    J Cardiovasc Electrophysiol; 2014 Feb; 25(2):197-207. PubMed ID: 24118558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
    Mirams GR; Cui Y; Sher A; Fink M; Cooper J; Heath BM; McMahon NC; Gavaghan DJ; Noble D
    Cardiovasc Res; 2011 Jul; 91(1):53-61. PubMed ID: 21300721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
    Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
    Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment.
    Di Veroli GY; Davies MR; Zhang H; Abi-Gerges N; Boyett MR
    Am J Physiol Heart Circ Physiol; 2013 Jan; 304(1):H104-17. PubMed ID: 23103500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
    Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
    J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
    Thomas D; Karle CA; Kiehn J
    Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
    Polak S; Wiśniowska B; Brandys J
    J Appl Toxicol; 2009 Apr; 29(3):183-206. PubMed ID: 18988205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revisiting the hERG safety margin after 20 years of routine hERG screening.
    Leishman DJ; Abernathy MM; Wang EB
    J Pharmacol Toxicol Methods; 2020 Sep; 105():106900. PubMed ID: 32768644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. hERG trafficking inhibition in drug-induced lethal cardiac arrhythmia.
    Nogawa H; Kawai T
    Eur J Pharmacol; 2014 Oct; 741():336-9. PubMed ID: 24998878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
    Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
    J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities.
    Marostica E; Van Ammel K; Teisman A; Boussery K; Van Bocxlaer J; De Ridder F; Gallacher D; Vermeulen A
    J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):659-79. PubMed ID: 26259721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dehydroevodiamine and hortiamine, alkaloids from the traditional Chinese herbal drug Evodia rutaecarpa, are I
    Baburin I; Varkevisser R; Schramm A; Saxena P; Beyl S; Szkokan P; Linder T; Stary-Weinzinger A; van der Heyden MAG; Houtman M; Takanari H; Jonsson M; Beekman JHD; Hamburger M; Vos MA; Hering S
    Pharmacol Res; 2018 May; 131():150-163. PubMed ID: 29477480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
    Wiśniowska B; Mendyk A; Fijorek K; Glinka A; Polak S
    J Appl Toxicol; 2012 Oct; 32(10):858-66. PubMed ID: 22761000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier potassium current.
    Witchel HJ; Hancox JC
    Clin Exp Pharmacol Physiol; 2000 Oct; 27(10):753-66. PubMed ID: 11022966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of Dynamic Occupancy, Binding Kinetics, and Channel Gating Kinetics for hERG Blocker Safety Assessment and Mitigation.
    Pearlstein RA; MacCannell KA; Erdemli G; Yeola S; Helmlinger G; Hu QY; Farid R; Egan W; Whitebread S; Springer C; Beck J; Wang HR; Maciejewski M; Urban L; Duca JS
    Curr Top Med Chem; 2016; 16(16):1792-818. PubMed ID: 26975508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of hERG1a and hERG1b isoforms on drug safety screening in iPSC-CMs.
    Goversen B; Jonsson MK; van den Heuvel NH; Rijken R; Vos MA; van Veen TA; de Boer TP
    Prog Biophys Mol Biol; 2019 Dec; 149():86-98. PubMed ID: 30826123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimized J to T peak and T peak to T end measurements in nonclinical species administered moxifloxacin and amiodarone.
    Bartko TM; Lutgen SM; Ross RA; Walisser JA; Garske EP; Kopelke KR; Ashcroft-Hawley K; Tang HM; Kremer JJ; Friedrichs GS; Nichols JV
    J Pharmacol Toxicol Methods; 2024; 128():107527. PubMed ID: 38852685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
    Finlayson K; Witchel HJ; McCulloch J; Sharkey J
    Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mechanism for the potential proarrhythmic effect of acidosis, bradycardia, and hypokalemia on the blockade of human ether-a-go-go-related gene (HERG) channels.
    Lin C; Cvetanovic I; Ke X; Ranade V; Somberg J
    Am J Ther; 2005; 12(4):328-36. PubMed ID: 16041196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro.
    Fanoe S; Jensen GB; Sjøgren P; Korsgaard MP; Grunnet M
    Br J Clin Pharmacol; 2009 Feb; 67(2):172-9. PubMed ID: 19159406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.